Skip to main content
. 2014 Dec 5;9(12):e114246. doi: 10.1371/journal.pone.0114246

Table 2. MVND and MPND analysis in glioma.

WHO II (n = 12) WHO III (n = 12) WHO IV (n = 16)
CD34+-MVND 14.90±4.67 25.83±12.73a 29.41±18.06a
α-SMA+-MVND 5.30±3.07 12.89±6.01a 22.45±14.72ab
α-SMA+/CD34+ MVND (%) 35.57 49.90 76.36
MPND 8.65±4.45 37.08±28.79a 81.61±69.85ab

a, P<0.01 vs grade II; b, P<0.01 vs grade III.

MVND, microvessel number/400 x field; MPND, α-SMA+ cell number in microvessel/400 x field.